Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,542
  • Shares Outstanding, K 119,103
  • Annual Sales, $ 5,420 K
  • Annual Income, $ -40,380 K
  • 60-Month Beta 0.93
  • Price/Sales 26.39
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ACRX with:

Options Overview

Details
  • Implied Volatility 242.54%
  • Historical Volatility 92.91%
  • IV Percentile 84%
  • IV Rank 35.95%
  • IV High 480.09% on 09/08/20
  • IV Low 109.18% on 06/07/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 290
  • Volume Avg (30-Day) 855
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 27,718
  • Open Int (30-Day) 24,952

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 unch
on 08/04/21
1.5500 -25.81%
on 07/14/21
-0.1900 (-14.18%)
since 07/02/21
3-Month
1.0200 +12.75%
on 05/13/21
1.6700 -31.14%
on 06/08/21
-0.0200 (-1.71%)
since 05/04/21
52-Week
1.0200 +12.75%
on 05/13/21
2.9400 -60.88%
on 02/09/21
+0.0200 (+1.77%)
since 08/04/20

Most Recent Stories

More News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Rocket, 360 DigiTech, and Piedmont Lithium and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of AcelRx Pharmaceuticals, Inc. (NASDAQ:...

ACRX : 1.1500 (-4.17%)
RKT : 17.45 (+0.87%)
QFIN : 21.48 (+2.43%)
PLL : 56.34 (+1.46%)
FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with LARGE LOSSES to Secure Counsel Before Final August 9 Deadline in Securities Class Action - ACRX

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) between March 17,...

ACRX : 1.1500 (-4.17%)
MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 4, 2021) - , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)...

ACRX : 1.1500 (-4.17%)
ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021

New York, New York--(Newsfile Corp. - August 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or...

ACRX : 1.1500 (-4.17%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class...

ACRX : 1.1500 (-4.17%)
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...

ACRX : 1.1500 (-4.17%)
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 3, 2021) - , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ("AcelRx"...

ACRX : 1.1500 (-4.17%)
ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the...

ACRX : 1.1500 (-4.17%)
Will AcelRx Pharmaceuticals (ACRX) Report Negative Q2 Earnings? What You Should Know

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRX : 1.1500 (-4.17%)
FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 2, 2021 / , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ('AcelRx' or 'the Company')...

ACRX : 1.1500 (-4.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

3rd Resistance Point 1.2167
2nd Resistance Point 1.2033
1st Resistance Point 1.1767
Last Price 1.1500
1st Support Level 1.1367
2nd Support Level 1.1233
3rd Support Level 1.0967

See More

52-Week High 2.9400
Fibonacci 61.8% 2.2066
Fibonacci 50% 1.9800
Fibonacci 38.2% 1.7534
Last Price 1.1500
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar